Mouse Models of Tumor Immunotherapy
- PMID: 26922998
- DOI: 10.1016/bs.ai.2015.12.004
Mouse Models of Tumor Immunotherapy
Abstract
Immunotherapy is now evolving into a major therapeutic option for cancer patients. Such clinical advances also promote massive interest in the search for novel immunotherapy targets, and to understand the mechanism of action of current drugs. It is projected that a series of novel immunotherapy agents will be developed and assessed for their therapeutic activity. In light of this, in vivo experimental mouse models that recapitulate human malignancies serve as valuable tools to validate the efficacy and safety profile of immunotherapy agents, before their transition into clinical trials. In this review, we will discuss the major classes of experimental mouse models of cancer commonly used for immunotherapy assessment and provide examples to guide the selection of appropriate models. We present some new data concerning the utility of a carcinogen-induced tumor model for comparing immunotherapies and combining immunotherapy with chemotherapy. We will also highlight some recent advances in experimental modeling of human malignancies in mice that are leading towards personalized therapy in patients.
Keywords: Carcinogen; Gene-engineered; Immunotherapy; Metastasis; Mouse tumor models; Resistance; T cell.
© 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. Epub 2016 Jan 22. Adv Immunol. 2016. PMID: 26923000 Free PMC article.
-
Prospects for TIM3-Targeted Antitumor Immunotherapy.Cancer Res. 2011 Nov 1;71(21):6567-71. doi: 10.1158/0008-5472.CAN-11-1487. Epub 2011 Oct 18. Cancer Res. 2011. PMID: 22009533 Review.
-
Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.J Natl Cancer Inst. 1982 Jun;68(6):963-9. J Natl Cancer Inst. 1982. PMID: 6953275
-
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.J Clin Invest. 1998 Jan 15;101(2):429-41. doi: 10.1172/JCI1348. J Clin Invest. 1998. PMID: 9435316 Free PMC article.
-
Mouse Tumor Models for Advanced Cancer Immunotherapy.Int J Mol Sci. 2020 Jun 9;21(11):4118. doi: 10.3390/ijms21114118. Int J Mol Sci. 2020. PMID: 32526987 Free PMC article. Review.
Cited by
-
An NGS-based assay for accurate detection and quantification of immune gene expression in mouse tumor models.PLoS One. 2024 May 20;19(5):e0303171. doi: 10.1371/journal.pone.0303171. eCollection 2024. PLoS One. 2024. PMID: 38768113 Free PMC article.
-
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.BMC Med. 2024 Apr 24;22(1):174. doi: 10.1186/s12916-024-03389-w. BMC Med. 2024. PMID: 38658988 Free PMC article.
-
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.Cancers (Basel). 2022 Oct 18;14(20):5108. doi: 10.3390/cancers14205108. Cancers (Basel). 2022. PMID: 36291891 Free PMC article. Review.
-
An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.Acta Biochim Biophys Sin (Shanghai). 2022 Oct 25;54(10):1497-1506. doi: 10.3724/abbs.2022145. Acta Biochim Biophys Sin (Shanghai). 2022. PMID: 36269133 Free PMC article.
-
Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer.Int J Mol Sci. 2022 Aug 16;23(16):9195. doi: 10.3390/ijms23169195. Int J Mol Sci. 2022. PMID: 36012461 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
